Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)

BMC Infectious Diseases

Javier Díez-Domingo³  Julio A Vázquez⁵  Raquel Abad⁵  José A Moraño²  Francisco Santonja¹  Luis Acedo²  Javier Villanueva-Oller⁴  Rafael J Villanueva²  Lina Pérez-Breva³ 

[1] Departamento de Estadística e Investigación Operativa, Universidad de Valencia, Valencia, Spain;Instituto de Matemática Multidisciplinar, Edificio 8G 2° Floor, Universitat Politècnica de Valéncia, Camino de Vera s/n, 46022 Valencia, Spain;Centro Superior de Investigación en Salud Pública-Fundación para el Fomento de la Investigación Sanitaria y Biomédica de Comunidad Valencia (CSISP-FISABIO), Avd. Cataluña, Valencia, Spain;Centro de Estudios Superiores Felipe II, Aranjuez, Madrid, Spain;Instituto de Salud Carlos III, 28029 Majadahonda, Madrid, Spain

关键词: Vaccination programs;    Agent-based modelling;    Seroprotection study;    Meningococcal C conjugate vaccines;   

Others  :  1127757
DOI  :  10.1186/1471-2334-14-280

 received in 2013-10-17, accepted in 2014-04-21,  发布年份 2014

【 摘 要 】

Background

Meningococcal C (MenC) conjugate vaccines have controlled invasive diseases associated with this serogroup in countries where they are included in National Immunization Programs and also in an extensive catch-up program involving subjects up to 20 years of age. Catch-up was important, not only because it prevented disease in adolescents and young adults at risk, but also because it decreased transmission of the bacteria, since it was in this age group where the organism was circulating. Our objective is to develop a new vaccination schedule to achieve maximum seroprotection in these groups.

Methods

A recent study has provided detailed age-structured information on the seroprotection levels against MenC in Valencia (Spain), where vaccination is routinely scheduled at 2 months and 6 months, with a booster dose at 18 months of age. A complementary catch-up campaign was also carried out in n for children from 12 months to 19 years of age. Statistical analyses of these data have provided an accurate picture on the evolution of seroprotection in the last few years.

Results

An agent-based model has been developed to study the future evolution of the seroprotection histogram. We have shown that the optimum strategy for achieving high protection levels in all infants, toddlers and adolescents is a change to a 2 months, 12 months and 12 years of age vaccination pattern. If the new schedule were implemented in January 2014, high-risk subjects between 15-19 years of age would have very low seroprotection for the next 6 years, thereby threatening the program.

Conclusions

High protection levels and a low incidence of meningococcal C disease can be achieved in the future by means of a cost-free change in vaccination program. However, we recommend a new catch-up program simultaneous to the change in regular vaccination program.

【 授权许可】

   
2014 Pérez-Breva et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Trotter CL, Gay NJ, Edmunds WJ: The natural history of meningococcal carriage and disease. Epidemiol Infect 2006, 134:556-566.
• [2]Fernández S, Arreaza L, Santiago I, Malvar A, Berrón S, Vázquez JA, Hervada X, Gestal JJ: Carriage of a new epidemic strain of Neisseria meningitidis and its relationship with the incidence of meningococcal disease in Galicia, Spain. Epidemiol Infect 1999, 123:349-357.
• [3]Comité Asesor de Vacunas: Meningococo C. [http://vacunasaep.org/profesionales/enfermedades/meningococo-c webcite] (accessed May 9th, 2013).
• [4]Larrauri A, Cano R, Garcia M, Mateo S: Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005, 23:4097-4100.
• [5]Situación actual de la enfermedad meningocócica en España: Modificación de la pauta de vacunación frente a meningococo C. Available at: [https://www.msssi.gob.es/ciudadanos/proteccionSalud/infancia/docs/MenC_MARZO_2006.pdf webcite] (Accessed May 9th, 2013).
• [6]Pérez-Breva L, Martínez-Beneito MA, Alemán-Sánchez S, Morant-Talamante N, Pérez-Vilar S, Puig-Barberà J, Díez-Domingo J: Meningococcal, C conjugate vaccine coverage in Valencia, Spain. Estimation by a multiple imputation analysis. In Poster presentation at the 31st annual meeting of the European Society for Paediatric Infectious Diseases. Milan, Italy; May 28-June 1; 2013.
• [7]Pérez-Breva L, Alemán-Sánchez S, Morant-Talamante N, Abad-Torreblanca R, Sastre-Cantón M, Vázquez-Moreno J, Díez-Domingo J: Meningococcal, C seroprevalence study. Valencia. Spain. In Poster presentation at the 30th annual meeting of the European Society for Paediatric Infectious Diseases. May 8-12. Thessaloniki, Greece; 2012.
• [8]Diez-Domingo J, Planelles-Cantarino MV, Baldo-Torrenti JM, Úbeda-Sansano I, Jubert-Rosich A, Puig-Barberà J, Gutiérrez-Gimeno MV: Antibody persistence 12 months after a booster dose of Meningococcal-C conjugated vaccine in the second year of life. Pediatr Infect Dis J 2010, 29(8):768-770.
• [9]Revisión del programa de vacunación frente a enfermedad meningocócica por serogrupo C Available at [http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/MenC.pdf webcite] (Accessed, June 18, 2013).
• [10]Maslanka SE, Gheesling LL, Libutti DE, Donaldson KE, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, Kriz-Kuzemenska P, Lemmon RD, Lorange M, Peeters CC, Quataert S, Tai JY, Carlone GM, The Multilaboratory, Study Group: Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997, 4(2):156-67.
• [11]Portero-Alonso A, Pastor-Villalba E, Marín-Ivorra R, Escuder-Alejos A, Palau-Sendra T, Chapado-Gregorio S, Lluch-Rodrigo JA, Sánchez-Latorre V, Martínez-Sorando L, Sirera-Serrano M: Sistema de información vacunal (SIV). Available at: [http://www.sp.san.gva.es/biblioteca/publicaciones/MATERIAL/PUBLICACIONES/PROMO_SALUD/CSP/SISTEMA webcite_ INFORMACION_VACUNAL.PDF] (Accessed, April 22, 2013)
• [12]Valentian Institute of Statistics [http://www.ive.es webcite]
• [13]Optimizing strategies for meningococcal C disease vaccination in Valencia, Spain Data analysis at the webpage: [http://menc.imm.upv.es webcite]
• [14]Poellabauer EM, Pavlova BG, Fritsch S, Singer J, Neubauer C, Doralt J, Valenta-Singer B, Ehrlich HJ: Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®;) in infants. Vaccine 2013. [http://dx.doi.org/10.1016/j.vaccine.2013.04.070 webcite]
• [15]Cano R, Larrauri A, Mateo S, Alcalá B, Salcedo C, Vázquez JA: Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill 2004, 9:5-6.
• [16]Balmer P, Borrow R, Miller E: Impact of meningococcal C conjugate vaccine in the UK. Med Microbiol 2002, 51:717-722.
• [17]Fitzgerald M, O‘Donnell J, O‘Flanagan D, Cafferkey M, Murphy K: Meningococcal disease in Ireland since the introduction of meningococcal serogroup C conjugate vaccination. Euro Surveill 2004, 8(5):2376.
• [18]De Greef S, Ruijs H, Timen A, van Deuren M, de Vries M, de Melker H, Spanjaard L, Dankert J: First effects of meningococcal C vaccination campaign in Netherlands. Euro Surveill Weekly 2003, 7(30):2264.
• [19]Trotter CL, Gay NJ, Edmunds WJ: Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidem 2005, 162:89-100.